Rationale and baseline characteristics of PREVENT: A second-generation intervention trial in subjects at-risk (Prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis

Schizophrenia Bulletin

Volumn 37, Issue SUPPL. 2, 2011, Pages

  Bechdolf, Andreas ^a   Müller, Hendrik ^a   Stützer, Hartmut ^a   Wagner, Michael ^b   Maier, Wolfgang ^b   Lautenschlager, Marion ^c   Heinz, Andreas ^c   De Millas, Walter ^c   Janssen, Birgit ^d   Gaebel, Wolfgang ^d   Michel, Tanja Maria ^e   Schneider, Frank ^e   Lambert, Martin ^f   Naber, Dieter ^f   Brüne, Martin ^g   Krüger Özgürdal, Seza ^g   Wobrock, Thomas ^h   Riedel, Michael ⁱ   Klosterkötter, Joachim ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

aripiprazole; cognitive behavior therapy; early intervention; prevention; prodrome; psychosis; schizophrenia

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

ADULT; ARTICLE; AUDIO RECORDING; CLINICAL PRACTICE; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; FEMALE; FIRST EPISODE PSYCHOSIS; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SKILL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; PIPERAZINES; PLACEBOS; PSYCHOTIC DISORDERS; QUINOLONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052256495     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr083     Document Type: Article

References (64)

1. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as firstline agents: a network meta-analysis. JAMA. 2003;289:2534-2544. (Pubitemid 37430155)
2. Peters AL, Davidson MB, Schriger DL, Hasselbald V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis research group on the diagnosis of diabetes using glycosylated hemoglobin levels. JAMA. 1996;276:1246-1252. (Pubitemid 26337708)
3. Adams EK, Breen N, Joski PJ. Impact of the National Brest and Cervical Detection Program on mammography and pap test utilization among white, Hispanic, and African American women: 1996-2000. Cancer. 2007;109:348-358. (Pubitemid 46106219)
4. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863-865. (Pubitemid 34465065)
5. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60:21-23.
6. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67:131-142. (Pubitemid 38251443)
7. Klosterkö tter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58:158-164. (Pubitemid 32142753)
8. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull. 2009;35:5-8.
9. Ruhrmann S, Schultze-Lutter F, Salokangas RKR, et al. Prediction of psychosis in adolescents and young adults at high risk results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67:241-251.
10. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008; 65:28-37.
11. McGorry PD, Yung AR, Phillips LJ. The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull. 2003;29:771-790. (Pubitemid 38181956)
12. McGorry PD, Yung AR, Phillips LJ, et al. Can first episode psychosis be delayed or prevented? A randomized controlled trial of interventions during the prepsychotic phase of schizophrenia and related psychosis. Arch Gen Psychiatry. 2002;59:921-928.
13. Morrison AP, French P, Walford L, et al. A randomised controlled trial of early detection and cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br J Psychiatry. 2004;185:291-297. (Pubitemid 39331330)
14. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. November 11, 2010; doi:10.1016/j. schres.2010.10.015.
15. Bechdolf A, Wagner M, Ruhrmann S, et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2011 (in press).
16. McGlashan TH, Zipursky RB, Perkins D et al. A randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163:790-799. (Pubitemid 44464525)
17. Amminger GP, Schäfer MR, Papageorgiou K. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146-154.
18. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
19. Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726-732.
20. Bentall RP, Morrison AP. More harm than good: the case against using antipsychotic drugs to prevent severe mental illness. J Mental Health. 2002;11:351-365.
21. Bechdolf A, Phillips LJ, Francey S, et al. Recent approaches to psychological interventions for people at risk of psychosis. Eur Arch Psychiatry Clin Neurosci. 2006;256:159-173.
22. Angermeyer MC, Matschinger H. Public attitude towards psychiatric treatment. Acta Psychiatr Scand. 1996;94:326-336. (Pubitemid 26396308)
23. Lauber C, Nordt C, Falcato L, Rö ssler W. Lay recommendations on how to treat mental disorders. Soc Psychiatry Psychiatr Epidemiol. 2001;36:53-56.
24. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523-537.
25. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2011;6. CD004718.
26. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatr Scand. 2005;113:247-272.
27. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70:1206-1212.
28. Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry. 2010;51:390-431.
29. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res. 2010;123:30-36.
30. Bell RQ. Multiple-risk cohorts and segmenting risks as solutions to the problem of false positives in risk for the major psychoses. Psychiatry. 1992;55:370-381. (Pubitemid 23039194)
31. Klosterkoetter J, Ruhrmann S, Schultze-Lutter F, et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry. 2005;4:161-167.
32. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis. Br J Psychiatry. 1998;172(suppl 33):14-20.
33. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68:546-557. (Pubitemid 46663037)
34. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18:251-267. (Pubitemid 38393435)
35. El-Sayeh HGG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006; 2. CD004578.
36. Woods SW, Tully EM, Walsh BC. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry. 2007;51(suppl):96-101.
37. Kobayashi H, Morita K, Takeshi K. Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J Clin Psychopharmacol. 2009;29:421-425.
38. McGlashan TH, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003;61:7-18. (Pubitemid 36332135)
39. Bechdolf A, Gross S, Veith V. Untersuchungs-und Behandlungsmanual für den Prüfarzt zur Durchführung der körperlichen/Zusatz- Untersuchungen und des Clinical Managements plus Aripiprazol/Placebo bei Personen mit erhöhtem Psychoserisiko der klinischen Studie PREVENT (Secondary Prevention of Schizophrenia: A Randomized Controlled Trial) Version 2.0. Cologne, Germany: University of Cologne; 2007.
40. Bechdolf A, Knost B, Maier S, Schröder C, Hambrecht M, Wagner M. Psychological Intervention for Persons at Risk of Psychosis in the Early Prodromal State. 2nd revised version. Germany: University of Köln/Bonn; 2002.
41. Bechdolf A, Puetzfeld V, Guettgemanns J, Gross S. Cognitive Behaviour Therapy for People At-risk of Psychosis. A Treatment Manual. Bern, Switzerland: Hans Huber; 2010.
42. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. SchizophrBull. 1984;10:300-312.
43. Garety PA, Kuipers E, Fowler D, Freeman D, Bebbington PE. A cognitive model of the positive symptoms of psychosis. Psychol Med. 2001;31:189-195. (Pubitemid 32166387)
44. Bechdolf A, Veith V, Gross S, Wiessmann T, Geyer C, Klosterkoetter J. Kognitive Verhaltenstherapie bei Personen mit erhöhtem Psychoserisiko. Nervenheilkunde. 2008;27:981-987.
45. Beck AT. Depression: Causes and Treatment. Philadelphia: University of Pennsylvania Press; 1967.
46. Ruhrmann S, Schultze-Lutter F, Klosterkoetter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;3(suppl):162-167.
47. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkoetter J. Schizophrenia Proneness Instrument, Adult Version (SPI-A). Rome, Italy: Giovanni Fioriti Editore s.r.l; 2007.
48. Kay SR. The positive and negative symptom scale (PANSS) of schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
49. Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
50. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970.
51. Pukrop R, Schlaak V, Möller-Leimkü hler AM, et al. Reliability and validity of quality of life assessed by the short-form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. Psychiatr Res. 2003;119:63-79. (Pubitemid 36829419)
52. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders 4th ed Washington, DC: American Psychiatric Association; 1994.
53. Schooler N, Hogarty G,Weissman M. Social Adjustment Scale II (SAS II). In: Hargreaves WA, Attkinson CC, Sorenson JE, eds. Materials for Community Mental Health Program Evaluators: Publications 79-328.Washington, DC: US Department of health and Human Services; 1979:290-302.
54. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatr Scand. 1987; 76(suppl 334):1-100.
55. Chouinard G, Ross-Chauinard A, et al. Extrapyramidal symptoms rating. Am J Neurol Sci. 1980;7:233.
56. Tarrier N, Lewis S, Haddock G, Bental R, et al. Cognitive behavioural therapy in first-episode and early schizophrenia 18-month follow-up of a randomised controlled trial. Br J Psychiatry. 2004;184:231-239. (Pubitemid 38333762)
57. Haddock G, Devane S, Bradshaw T, et al. An investigation into the psychometric properties of the Cognitive Therapy Scale for Psychosis (CTSPsy). Behav Cogn Psychother. 2001; 29:221-233. (Pubitemid 32391073)
58. Wittorf A, Jakobi U, Klingberg S. German Translation of the CTS-PSY. Germany: University of Tübingen; 2007.
59. Tarrier N, Lewis S, et al. Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. Br J Psychiatry. 2004;184: 231-307.
60. Ruhrmann S, Bechdolf A, Kuehn KU, et al. LIPS study group acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry. 2007;51(suppl):88-95.
61. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35:894-908.
62. Rosen JL, Miller TJ, D'Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85:124-131. (Pubitemid 43947540)
63. Svirskis T, Korkeila J, Heinimaa M, et al. Axis-I disorders and vulnerability to psychosis. Schizophr Res. 2005;75:439-446. (Pubitemid 40693075)
64. Mrazek PJ, Haggerty RJ, eds. Reducing Risks for Mental Disorders. Frontiers for Preventive Intervention Research. Washington, DC: National Academy Press; 1994.